Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Active not recruiting 2Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 33Breast Neoplasms 27Carcinoma, Non-Small-Cell Lung 22Triple Negative Breast Neoplasms 19Ovarian Neoplasms 19Lung Neoplasms 18Fallopian Tube Neoplasms 18Neoplasm Metastasis 15Squamous Cell Carcinoma of Head and Neck 12Endometrial Neoplasms 10Neoplasms 9Oropharyngeal Neoplasms 6Mouth Neoplasms 6Esophageal Neoplasms 6Cholangiocarcinoma 6Melanoma 5Colorectal Neoplasms 5Carcinoma 5Adenocarcinoma Of Esophagus 5Stomach Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma, Transitional Cell 4Anatomic Stage I Breast Cancer AJCC v8 4Pancreatic Adenocarcinoma 3Inflammatory Breast Neoplasms 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Squamous Cell 3

Interventions

Cisplatin 26Paclitaxel 21pembrolizumab 15Radiotherapy 13Carboplatin 13tislelizumab 12Fluorouracil 12Drug Therapy 11Irinotecan 9toripalimab 8Esophagectomy 8Oxaliplatin 6Nivolumab 6Capecitabine 6Neoadjuvant Therapy 5Leucovorin 5Docetaxel 5lenvatinib 4camrelizumab 4Taxes 4Radiation 4Levoleucovorin 4Immune Checkpoint Inhibitors 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4spartalizumab 3sintilimab 3apatinib 3Itraconazole 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Taxes × 1 year × Clear all
NCT07618910 2026-06-01

Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC

Tang-Du Hospital

Phase 2 Not yet recruiting
33 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT01142388 2026-05-29

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
94 enrolled 8 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
3 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

NCT04548440 2025-06-12

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

Sun Yat-sen University

Phase 2 Completed
50 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡